There is no strong evidence available to support this practice in DCIS; it is mainly based on extrapolation of the ASCO/CAP algorithm for hormonal receptor status assessment in invasive breast cancer patients, although the ASCO/CAP expert panel considers PR IHC as optional [60]. The gene discussed is PGR; the disease is ductal breast carcinoma in situ.